A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease

Abstract Background Amyloid beta protein (Aβ) is a treatment target in Alzheimer’s Disease (AD). Lowering production of its parent protein, APP, has benefits in preclinical models. Posiphen, an orally administered small molecule, binds to an iron-responsive element in APP mRNA and decreases translat...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Douglas Galasko, Martin R. Farlow, Brendan P. Lucey, Lawrence S. Honig, Donald Elbert, Randall Bateman, Jeremiah Momper, Ronald G. Thomas, Robert A. Rissman, Judy Pa, Vahan Aslanyan, Archana Balasubramanian, Tim West, Maria Maccecchini, Howard H. Feldman
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2024-07-01
Serie:	Alzheimer’s Research & Therapy
Soggetti:	Alzheimer’s disease Amyloid beta protein APP Pharmacodynamics Clinical trial
Accesso online:	https://doi.org/10.1186/s13195-024-01490-z
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!